Project Grant R01CA312636
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $572K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Federal Project Grant Award Summary The University of Michigan received a $152,586 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 12, 2025, with completion scheduled for June 16, 2028. This award supports investigator-initiated research focused on elucidating the role of membrane-spanning 4A (MS4A14), a macrophage-expressed protein, in regulating anti-tumor immunity and immune checkpoint blockade (ICB) response. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan a $669,278 Project Grant (CFDA 93.395: Cancer Treatment Research) effective June 1, 2026, through May 31, 2031, to develop and validate a novel microbial-based cancer therapy platform. The research focuses on engineering nonpathogenic, tumor-tropic Escherichia coli bacteria to display membrane-anchored immune cytokines, specifically decoy-resistant interleukin-18 (DR-18), to enhance localized...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a Project Grant totaling $646,920 under the Cancer Treatment Research program (CFDA 93.395), effective March 11, 2026 through February 28, 2031. This award supports novel multi-targeted therapeutic strategies targeting T-cell lymphomas (TCL) and their tumor microenvironment. The research addresses the critical clinical challenge of chemotherapy-resistant TCL disease, for which...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $544,868 Project Grant to the Regents of the University of Michigan (Office of Research and Sponsored Projects) under the Cancer Treatment Research program (CFDA 93.395) for the period of June 1, 2026, through May 31, 2031. The research focuses on elucidating the mechanisms by which the tumor cell transporter SLC13A3 and the metabolite itaconate contribute to tumor resistance to immunotherapy. Specifically, the project...
- Federal Grant Award Summary The National Cancer Institute awarded $279,936 to the University of Michigan (Regents of the University of Michigan) under the Cancer Research Manpower program (CFDA 93.398) on July 15, 2025, for a project titled "Beyond Lysis: Deciphering the Role of Perforin-Mediated Ferroptosis in Anti-Tumor Immunity." The award supports biomedical research and training in cancer immunology through completion on June 30, 2027. The research aims to elucidate the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $136,412 to the Regents of the University of Michigan, effective August 1, 2025 through July 31, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at defining and interrupting metabolic crosstalk in the glioblastoma microenvironment. The research builds upon preliminary findings demonstrating that glioblastoma (GBM) tumors acquire nutrients through...
- Federal Grant Award Summary The National Cancer Institute awarded a $646,671 Project Grant to the Regents of the University of Michigan on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on antibody drug conjugate (ADC) immunotherapeutics. The research will be conducted at the University of Michigan in Ann Arbor through April 30, 2031. This project focuses on identifying novel payloads and optimizing high avidity low affinity (HALA) antibody designs to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $660,808 under the Cancer Biology Research program (CFDA 93.396) to investigate the durability and functional role of tissue-resident memory T cells (TRM) in melanoma immunotherapy response and survival outcomes. The research initiative, which commenced April 7, 2026 and extends through March 31, 2031, focuses on understanding how TRM cells—particularly a subset characterized...
- Federal Grant Award Summary The National Cancer Institute awarded $2.82 million to the Regents of the University of Michigan under the Cancer Treatment Research program (CFDA 93.395) on August 6, 2025, with completion targeted for July 31, 2029. This Project Grant supports the development of new methods to measure metabolic pathway activity in glioblastomas (GBMs), deadly brain cancers that rewire their metabolism to enable growth, invasion, and treatment resistance. The research deliverables...
- Federal Project Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects Division, received a $646,881 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research focused on developing and validating small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase enzyme...